Research
Hormonal
GLP-1-based therapies may accelerate the progression of premalignant pancreatic lesions (PanINs) to pancreatic cancer in individuals with pre-existing dysplasia, acting as a growth factor rather than an initiator.
If you are taking a GLP-1 drug, be aware of the potential risk of pancreatic cancer, especially if you have a family history of pancreatic cancer or chronic pancreatitis. The paper suggests this risk is real and mechanistically plausible, not just a rare side effect.
ModerateQualifiesMEDIUM confidence
Since progression of PanINs to pancreatic cancer is via the accumulation of additional somatic mutations, any driver of increased cellular replication in PanINs is likely to increase that probability.
Why this rating
Based on animal models (KrasG12D mice) and human histological data showing PanIN expansion, but no direct human epidemiological proof of causality yet.
Source
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Peter C. Butler et al. · Diabetes Care · 2013
DOI 10.2337/dc12-2713
narrative_reviewCited 294×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) are associated with a class-wide risk of acute pancreatitis, driven by a mechanism of supraphysiological GLP-1 receptor activation causing exocrine pancreatic duct proliferation and potential occlusion.Moderate
- GLP-1-based therapies are associated with an increased risk of thyroid cancer, specifically medullary thyroid cancer and papillary thyroid cancer, due to GLP-1 receptor expression in thyroid C-cells and papillary cancer cells.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →